Previous 10 | Next 10 |
2024-02-13 00:39:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-02-12 08:40:44 ET More on Corteva Corteva Q4: Strong Positive Tone With Crop Protection Normalization (Upgrade) Corteva, Inc. (CTVA) Q4 2023 Earnings Call Transcript Corteva, Inc. 2023 Q4 - Results - Earnings Call Presentation Corteva surges after foreca...
2024-02-08 14:03:23 ET In 2023, Corteva's cost of goods sold (COGS) decreased to $9,920 million (58% of net sales) compared to $10,436 million (60% of net sales) in 2022. This decrease was driven by lower volumes, ongoing cost and productivity actions, and a decrease in royalty expenses. Howe...
2024-02-08 12:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-06 11:19:31 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value 30 most inexpensive stocks with the highest exposure to China sales - Goldman Stocks most at risk if the Fed reasserts higher-for-longer - JPM ...
2024-02-02 13:30:02 ET Oppenheimer analyst issues OUTPERFORM recommendation for CTVA on February 2, 2024 01:34PM ET. The previous analyst recommendation was Outperform. CTVA was trading at $53.25 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-02-02 13:30:01 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTVA on February 2, 2024 01:34PM ET. The previous analyst recommendation was Equal-Weight. CTVA was trading at $53.25 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-02-02 09:26:48 ET Summary Corteva released Q4 FY23 results, surpassing market expectations. The company focused on margin improvement and achieved robust margin expansion. The management expressed a positive outlook for the future, anticipating growth in the seed business...
2024-02-02 05:30:02 ET Exane BNP Paribas analyst issues NEUTRAL recommendation for CTVA on February 2, 2024 04:02AM ET. CTVA was trading at $54.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 10 - Buy,...
Corteva, Inc. (NYSE: CTVA) is one of today's top gainers. The company's shares have moved 0.84% on the day to $48.22. Corteva, Inc. operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and tr...
News, Short Squeeze, Breakout and More Instantly...
Corteva Inc. Company Name:
CTVA Stock Symbol:
NYSE Market:
Corteva to Participate in the 2024 BMO Farm to Market Chemicals Conference PR Newswire INDIANAPOLIS , May 8, 2024 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) announces that Executive Vice President and Chief Financial Officer, Dave Anderson , and Executive Vic...
Corteva Reports First Quarter 2024 Results, Reaffirms 2024 Guidance PR Newswire 1Q results in line with expectations and mostly constructive ag economy Strength of Seed performance demonstrates global demand for top technology Crop P...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...